Croda commits to Science Based Targets for reduction of greenhouse gas emissions
Group aiming to achieve a 50% reduction in absolute GHG emissions based on 2006 levels by 2030 and an 80% reduction by 2050.
Croda International has announced its commitment to reduce its greenhouse gas emissions in line with the Science Based Targets initiative.
Croda is one of the few companies within the speciality chemicals sector to commit to Science Based Targets (SBT), with the aim of restricting global warming to 1.5 °C above the pre-industrial average. With reductions in greenhouse gas emissions (GHG) a priority, Croda has already established Group targets to achieve a 50% reduction in absolute GHG emissions based on 2006 levels by 2030 and an 80% reduction by 2050.
With more than 60% of the company’s raw materials already coming from bio-based sources, Croda believes that that they are well positioned to not only reduce their GHG emissions, but to become ‘Climate Positive’. This ambitious target will focus on the use of more bio-based raw materials, and also through the ongoing work that Croda is undertaking to quantify the carbon savings derived from their products as they are used by their customers and the end consumers. In 2018, over 700,000 tonnes of GHG emissions were avoided through just four of Croda’s products in application. For example, Croda’s Coltide RadianceTM extends the lifetime of clothes, avoiding additional carbon and water intensive manufacture.
Terry Thistlethwaite, Vice President of Sustainability at Croda said: “We are proud to be one of around 600 companies taking science-based climate action and reducing greenhouse gas emissions by committing to Science Based Targets.
"Our business purpose is to use Smart Science to Improve Lives; this is just one area where we are pushing ourselves and supporting our customers to have a positive impact on the planet and society. We will continue to lead the speciality chemicals industry with our approach to sustainability.”
The Science Based Targets initiative is a collaboration between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). It signals an acceleration in the transition to a low carbon economy and supports companies who are already demonstrating they have the skills, expertise and ingenuity to make this a reality.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.